Compare Royal Caribbean Cruises Ltd (RCL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs Zoetis Inc — how do they compare? Royal Caribbean Cruises Ltd trades at $260.9 (market cap $70.74B), while Zoetis Inc trades at $73.65 (market cap $30.40B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 2.3× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| RCL | ZTS | |
|---|---|---|
Market Cap | $70.74B | $30.40B |
Sector | Consumer Cyclical | Health |
52-Week High | $350.23 | $150.61 |
52-Week Low | $246.71 | $71.91 |
Enterprise Value | $93.38B | $37.96B |
Dividend Yield | 2.27% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $264.5, down 0.26% on the day, with a bearish technical signal from moving averages but bullish oscillators. The stock shows strong fundamentals with Q2 2026 EPS beating expectations at $4.21 versus $3.98, and robust profitability margins including a 23.54% net income margin. Recent news highlights dividend declarations and institutional buying interest, though oil price increases pose near-term headwinds for cruise operators.
The outlook remains positive with analyst consensus price target of $367.83 implying significant upside, supported by earnings growth and debt reduction trends. Key risks include fuel cost volatility from rising oil prices and macroeconomic sensitivity, but institutional accumulation and strong cash flows provide a solid foundation for long-term investors.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
